Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Jun;51(6):781–782. doi: 10.1136/ard.51.6.781

Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis.

Y Tokano 1, Y Kanai 1, H Hashimoto 1, K Okumura 1, S Hirose 1
PMCID: PMC1004746  PMID: 1616363

Abstract

The concentration of soluble interleukin 2 receptor was determined in serum samples from 19 patients with polymyositis/dermatomyositis by an enzyme linked immunosorbent assay (ELISA). The concentration of soluble interleukin 2 receptor in serum samples from patients with polymyositis/dermatomyositis was higher than that in samples from normal subjects.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bohan A., Peter J. B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344–347. doi: 10.1056/NEJM197502132920706. [DOI] [PubMed] [Google Scholar]
  2. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  3. Degiannis D., Seibold J. R., Czarnecki M., Raskova J., Raska K., Jr Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum. 1990 Mar;33(3):375–380. doi: 10.1002/art.1780330310. [DOI] [PubMed] [Google Scholar]
  4. Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988 Jul;31(7):844–849. doi: 10.1002/art.1780310704. [DOI] [PubMed] [Google Scholar]
  5. Miller F. W., Love L. A., Barbieri S. A., Balow J. E., Plotz P. H. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol. 1990 Sep;81(3):373–379. doi: 10.1111/j.1365-2249.1990.tb05341.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Symons J. A., Wood N. C., Di Giovine F. S., Duff G. W. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988 Oct 15;141(8):2612–2618. [PubMed] [Google Scholar]
  7. Tokano Y., Murashima A., Takasaki Y., Hashimoto H., Okumura K., Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis. 1989 Oct;48(10):803–809. doi: 10.1136/ard.48.10.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  9. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES